Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial.
Saved in:
| Title: | Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. |
|---|---|
| Authors: | File TM Jr; Summa Health, Akron, OH, USA.; Northeast Ohio Medical University, Rootstown, OH, USA., Kaye KS; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Ihor S; Communal Non-commercial Enterprise 'City Polyclinic No. 9' of the Kharkiv City Council, Kharkiv, Ukraine., Hovbakh I; Communal Non-commercial Enterprise 'City Polyclinic No. 9' of the Kharkiv City Council, Kharkiv, Ukraine., Katsarava V; Tbilisi State Medical University and Ingorokva State High Technology Medical Clinic, Tbilisi, Georgia., Kirsch C; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA., Soni K; MMS Holdings Canton, MI, USA., Gupta K; MMS Holdings Canton, MI, USA., Manley A; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA., Deck DH; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA., Anastasiou D; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA., Chitra S; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA., Villano S; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA. |
| Source: | EClinicalMedicine [EClinicalMedicine] 2025 Nov 20; Vol. 90, pp. 103656. Date of Electronic Publication: 2025 Nov 20 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41340860 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22File+TM+Jr%22">File TM Jr</searchLink>; Summa Health, Akron, OH, USA.; Northeast Ohio Medical University, Rootstown, OH, USA.<br /><searchLink fieldCode="AU" term="%22Kaye+KS%22">Kaye KS</searchLink>; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Ihor+S%22">Ihor S</searchLink>; Communal Non-commercial Enterprise 'City Polyclinic No. 9' of the Kharkiv City Council, Kharkiv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Hovbakh+I%22">Hovbakh I</searchLink>; Communal Non-commercial Enterprise 'City Polyclinic No. 9' of the Kharkiv City Council, Kharkiv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Katsarava+V%22">Katsarava V</searchLink>; Tbilisi State Medical University and Ingorokva State High Technology Medical Clinic, Tbilisi, Georgia.<br /><searchLink fieldCode="AU" term="%22Kirsch+C%22">Kirsch C</searchLink>; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Soni+K%22">Soni K</searchLink>; MMS Holdings Canton, MI, USA.<br /><searchLink fieldCode="AU" term="%22Gupta+K%22">Gupta K</searchLink>; MMS Holdings Canton, MI, USA.<br /><searchLink fieldCode="AU" term="%22Manley+A%22">Manley A</searchLink>; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Deck+DH%22">Deck DH</searchLink>; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Anastasiou+D%22">Anastasiou D</searchLink>; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Chitra+S%22">Chitra S</searchLink>; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Villano+S%22">Villano S</searchLink>; Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101733727%22">EClinicalMedicine</searchLink> [EClinicalMedicine] 2025 Nov 20; Vol. 90, pp. 103656. <i>Date of Electronic Publication: </i>2025 Nov 20 (<i>Print Publication: </i>2025). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22The+Lancet%22">The Lancet </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101733727 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2589-5370 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225895370%22">25895370 </searchLink><i>NLM ISO Abbreviation: </i>EClinicalMedicine <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41340860 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.eclinm.2025.103656 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 103656 Titles: – TitleFull: Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: File TM Jr – PersonEntity: Name: NameFull: Kaye KS – PersonEntity: Name: NameFull: Ihor S – PersonEntity: Name: NameFull: Hovbakh I – PersonEntity: Name: NameFull: Katsarava V – PersonEntity: Name: NameFull: Kirsch C – PersonEntity: Name: NameFull: Soni K – PersonEntity: Name: NameFull: Gupta K – PersonEntity: Name: NameFull: Manley A – PersonEntity: Name: NameFull: Deck DH – PersonEntity: Name: NameFull: Anastasiou D – PersonEntity: Name: NameFull: Chitra S – PersonEntity: Name: NameFull: Villano S IsPartOfRelationships: – BibEntity: Dates: – D: 20 M: 11 Text: 2025 Nov 20 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2589-5370 Numbering: – Type: volume Value: 90 Titles: – TitleFull: EClinicalMedicine Type: main |
| ResultId | 1 |
